Unicycive Therapeutics (UNCY) Stock: Buy, Sell, or Hold?
UNCY - Unicycive Therapeutics, Inc. Common Stock
$3.89
-0.05 (-1.27%)
▼
5d:
+15.77%
30d:
-19.13%
90d:
-24.17%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When UNCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: UNCY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: UNCY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.54
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$2.20
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UNCY is currently trading at $3.89, which is considered slightly low relative to its 30-day fair value range of $3.82 to $4.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.3) compared to its historical average (1.5). At these levels, the market is pricing in 17.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UNCY is in a strong downtrend. Immediate support is located at $3.35, while resistance sits at $4.18.
Market Sentiment: UNCY scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $28.40 (+620.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, UNCY is in a strong downtrend. Immediate support is located at $3.35, while resistance sits at $4.18.
Market Sentiment: UNCY scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $28.40 (+620.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.82 -
$4.79
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (84/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 620.8% below Wall St target ($28.40)
- NEUTRAL: Trading at premium valuation - market expects 17.2% growth which is achievable
- BULLISH: Bottoming setup score 84/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$3.82 -
$4.79
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.35
Resistance Level
$4.18
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.34
Wall Street Target
$28.40
(+620.8%)
Valuation Premium vs History
+17.2% premium
PE vs Historical
2.3 vs 1.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+17.2%
(market-implied from PE analysis)
1-Year Target
$4.62
(+17%)
2-Year Target
$5.41
(+37%)
3-Year Target
$6.34
(+61%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$4.07
(+3%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 23, 2026 4:22 PM ET
Data refreshes hourly during market hours. Next update: 5:22 PM
Data refreshes hourly during market hours. Next update: 5:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UNCY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 61 BUY |
